Break it Down: Optiscan Imaging to transform digital pathology

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Optiscan’s (ASX:OIL) major milestone in developing its cloud-based telepathology platform, with the completion of its beta phase in the hopes of transforming digital pathology.

The platform, developed in partnership with Prolucid Technologies, uses Optiscan’s MedTech product.

Tune in to get the latest.

While Optiscan Imaging is a Stockhead advertiser, it did not sponsor this content.